Psoriatic Arthritis
Latest News
New 46-week PsA data released for IL-17A inhibitor izokibep
Long-term data build on statistically significant improvements demonstrated at 16 weeks across key measures of joint pain, psoriasis, and...
Feature
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and...
News from the FDA/CDC
FDA approves new formulation of Hyrimoz adalimumab biosimilar
The agency approved a higher-concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
Latest News
New data forecast more oral PDE4 inhibitors for psoriasis
The phase 2b data suggest that the drug, called orismilast, “is a potential new addition to the psoriasis armamentarium,” said Lars E. French, MD...
From the Journals
Psoriatic arthritis treatment for women falls short, study suggests
Women with psoriatic arthritis who were treated with ustekinumab or a tumor necrosis factor inhibitor had lower response rates and persistence at...
From the Journals
Biologics show signs of delaying arthritis in psoriasis patients
Treatment with the interleukin-12/23 inhibitor ustekinumab or interleukin-23 inhibitors (guselkumab, risankizumab, tildrakizumab) was linked to a...
From the Journals
Isolated nail psoriasis may bring arthritis into play
The review of 20 years of cases show delayed diagnosis, delineate clinical features, and suggest a relationship with PsA.
Latest News
Treating nail psoriasis: Intralesional injections and biologics
When Dr. Armstrong performs intramatricial injections, she uses triamcinolone acetonide at 10 mg/mL.
Feature
What’s holding back physicians from prescribing biosimilars? Four specialties weigh in
Physicians surveyed from four different specialties reported that they were generally comfortable prescribing biosimilars, but greater discounts...
Latest News
New influx of Humira biosimilars may not drive immediate change
As many as 8-10 adalimumab biosimilars are anticipated to come on the market this year, giving mainstay drug Humira some vigorous competition.
Latest News
What does the future of psoriasis treatment look like?
“We have terrific drugs for psoriasis, but how can we do better?” Dr. Andrew Blauvelt asked.